+

WO2001077107A8 - Production et utilisation de composes heterocycliques - Google Patents

Production et utilisation de composes heterocycliques

Info

Publication number
WO2001077107A8
WO2001077107A8 PCT/JP2001/002937 JP0102937W WO0177107A8 WO 2001077107 A8 WO2001077107 A8 WO 2001077107A8 JP 0102937 W JP0102937 W JP 0102937W WO 0177107 A8 WO0177107 A8 WO 0177107A8
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
oxazole derivatives
formula
alkyl
Prior art date
Application number
PCT/JP2001/002937
Other languages
English (en)
Other versions
WO2001077107B1 (fr
WO2001077107A1 (fr
Inventor
Akihiro Tasaka
Takenori Hitaka
Etsuya Matsutani
Original Assignee
Takeda Chemical Industries Ltd
Akihiro Tasaka
Takenori Hitaka
Etsuya Matsutani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA02009621A priority Critical patent/MXPA02009621A/es
Priority to PL01365787A priority patent/PL365787A1/xx
Priority to EP01917827A priority patent/EP1268473A1/fr
Priority to SK1413-2002A priority patent/SK14132002A3/sk
Priority to BR0109851-9A priority patent/BR0109851A/pt
Priority to US09/889,974 priority patent/US6716863B2/en
Priority to AU2001244726A priority patent/AU2001244726A1/en
Priority to CA002404760A priority patent/CA2404760A1/fr
Priority to HU0300434A priority patent/HUP0300434A3/hu
Priority to KR1020017011568A priority patent/KR20020028865A/ko
Application filed by Takeda Chemical Industries Ltd, Akihiro Tasaka, Takenori Hitaka, Etsuya Matsutani filed Critical Takeda Chemical Industries Ltd
Priority to IL15211501A priority patent/IL152115A0/xx
Priority to EEP200200576A priority patent/EE200200576A/xx
Publication of WO2001077107A1 publication Critical patent/WO2001077107A1/fr
Publication of WO2001077107B1 publication Critical patent/WO2001077107B1/fr
Priority to NO20024742A priority patent/NO20024742L/no
Publication of WO2001077107A8 publication Critical patent/WO2001077107A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé, ou un de ses sels, représenté par la formule (1) dans laquelle m prend la valeur 1 ou 2, R1 représente un halogène ou un groupe alkyle en C¿1-2? éventuellement halogéné, l'un des R?2 et R3¿ représente un atome d'hydrogène et l'autre représente un groupe de formule (2) ou (3) dans laquelle n prend la valeur 3 ou 4, et R4 représente un groupe alkyle en C¿1-4? substitué par 1 ou 2 groupes hydroxy. Ce composé possède une activité inhibitrice de tyrosine kinase.
PCT/JP2001/002937 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques WO2001077107A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
HU0300434A HUP0300434A3 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
EP01917827A EP1268473A1 (fr) 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques
SK1413-2002A SK14132002A3 (sk) 2000-04-07 2001-04-05 Deriváty oxazolu, spôsob ich výroby a použitia a farmaceutický prostriedok
BR0109851-9A BR0109851A (pt) 2000-04-07 2001-04-05 Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
US09/889,974 US6716863B2 (en) 2000-04-07 2001-04-05 Heterocyclic compounds their production and use
AU2001244726A AU2001244726A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors
CA002404760A CA2404760A1 (fr) 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques
MXPA02009621A MXPA02009621A (es) 2000-04-07 2001-04-05 Derivados de oxazol y sus usos como inhibidores de tirosina cinasa.
PL01365787A PL365787A1 (en) 2000-04-07 2001-04-05 Heterocyclic compounds, their production and use
KR1020017011568A KR20020028865A (ko) 2000-04-07 2001-04-05 복소환식 화합물, 그의 제조 및 용도
IL15211501A IL152115A0 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors
EEP200200576A EE200200576A (et) 2000-04-07 2001-04-05 Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
NO20024742A NO20024742L (no) 2000-04-07 2002-10-02 Heterocykliske forbindelser, deres fremstilling og anvendelse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-106836 2000-04-07
JP2000106836 2000-04-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/889,974 A-371-Of-International US6716863B2 (en) 2000-04-07 2001-04-05 Heterocyclic compounds their production and use
US10/620,706 Division US20040024035A1 (en) 2000-04-07 2003-07-17 Heterocyclic compounds, their production and use

Publications (3)

Publication Number Publication Date
WO2001077107A1 WO2001077107A1 (fr) 2001-10-18
WO2001077107B1 WO2001077107B1 (fr) 2001-12-20
WO2001077107A8 true WO2001077107A8 (fr) 2003-02-13

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002937 WO2001077107A1 (fr) 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques

Country Status (19)

Country Link
US (2) US6716863B2 (fr)
EP (1) EP1268473A1 (fr)
KR (1) KR20020028865A (fr)
CN (1) CN1444582A (fr)
AU (1) AU2001244726A1 (fr)
BR (1) BR0109851A (fr)
CA (1) CA2404760A1 (fr)
CO (1) CO5261589A1 (fr)
CZ (1) CZ20023264A3 (fr)
EE (1) EE200200576A (fr)
HU (1) HUP0300434A3 (fr)
IL (1) IL152115A0 (fr)
MX (1) MXPA02009621A (fr)
NO (1) NO20024742L (fr)
OA (1) OA12244A (fr)
PE (1) PE20011178A1 (fr)
PL (1) PL365787A1 (fr)
SK (1) SK14132002A3 (fr)
WO (1) WO2001077107A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103761A3 (en) * 1998-10-08 2002-11-28 Takeda Chemical Industries Ltd Compositions for retarding change of hormone-dependent cancer into hormone-independent cancer and their use
EP1310491A1 (fr) * 2000-07-19 2003-05-14 Takeda Chemical Industries, Ltd. Procede de fabrication d'un derive de 1,2,3 triasol substitue en position 1
US20040235748A1 (en) * 2001-04-25 2004-11-25 Yasutaka Igari Agents for preventing postoperative recurrence of premenopausal breast cancer
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
US20050215528A1 (en) * 2001-08-10 2005-09-29 Shuichi Furuya Gnrh agonist combination drugs
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
AU2002349477A1 (en) * 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
WO2003059907A1 (fr) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Composes heterocycliques azotes : procede de preparation et d'utilisation
EP1572083A4 (fr) 2002-04-25 2008-09-24 Univ Connecticut Health Ct Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal
RS58025B1 (sr) * 2002-12-16 2019-02-28 Kissei Pharmaceutical Co Ltd Lekovi u čvrstom stanju za oralnu upotrebu
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200423931A (en) * 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
US7247649B2 (en) * 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200612914A (en) 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
EP1758897A1 (fr) 2004-04-02 2007-03-07 F.Hoffmann-La Roche Ag Derives de diazine, fabrication et utilisation de ceux-ci comme agents pharmaceutiques
US7005526B2 (en) 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
AR050944A1 (es) * 2004-09-22 2006-12-06 Hoffmann La Roche Derivados de indol, su fabricacion y su utilizacion como agentes farmaceuticos
AR050652A1 (es) * 2004-09-24 2006-11-08 Hoffmann La Roche Derivados de oxazol, preparacion y uso como inhibidores de la tirosina quinasa
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US7429605B2 (en) * 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
EP1915370A1 (fr) * 2005-08-08 2008-04-30 F.Hoffmann-La Roche Ag Derives de pyrazole, leur fabrication et leur utilisation comme agents pharmaceutiques
CA2622944A1 (fr) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Derives de diazine azole, leur fabrication et leur utilisation en tant qu'agents pharmaceutiques
WO2008034579A1 (fr) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag Derives de 2-heterocyclyl-5-phenoxymethylpyridine utilises en tant qu'agents anticancereux
MX2009006315A (es) 2006-12-12 2009-10-13 Takeda Pharmaceutical Compuesto heterociclico fusionado.
JP5328643B2 (ja) 2007-04-20 2013-10-30 大同化成工業株式会社 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
US20090233937A1 (en) 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2010036917A1 (fr) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prévention et traitement d'un cancer avec mutation du gène ras
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
RU2517111C2 (ru) 2009-09-30 2014-05-27 Кабусики Кайся Санги Способ повышения водорастворимости слаборастворимых веществ
JP5705206B2 (ja) 2010-02-26 2015-04-22 日新化成株式会社 硬カプセルおよびその製造方法
WO2011153049A1 (fr) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Procédés et utilisation de composés se liant au complexe récepteur her2/neu
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
JP6225113B2 (ja) 2012-09-26 2017-11-01 武田薬品工業株式会社 固体粒子の製造方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3795609B1 (fr) 2015-07-01 2024-04-03 California Institute of Technology Systèmes d'administration à base de polymère d'acide mucique cationique
EP3238711B1 (fr) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base pour dispersion solide, procédé de production d'une dispersion solide l'utilisant et dispersion solide
CA2995617A1 (fr) 2017-11-03 2019-05-03 Universite De Montreal Inhibiteurs d'activite mitochondrique heterocycliques et utilisations associees
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97872A (en) 1990-04-16 1996-07-23 Rhone Poulenc Rorer Int Pharmaceutical compositions containing styryl-substituted monocylic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase and a compounds of this type
EP0912562A1 (fr) * 1996-07-19 1999-05-06 Takeda Chemical Industries, Ltd. Composes heterocycliques, leur production et leur utilisation

Also Published As

Publication number Publication date
WO2001077107B1 (fr) 2001-12-20
CA2404760A1 (fr) 2001-10-18
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
IL152115A0 (en) 2003-05-29
KR20020028865A (ko) 2002-04-17
HUP0300434A3 (en) 2004-11-29
CO5261589A1 (es) 2003-03-31
SK14132002A3 (sk) 2003-04-01
OA12244A (en) 2006-05-10
NO20024742L (no) 2002-11-25
AU2001244726A1 (en) 2001-10-23
NO20024742D0 (no) 2002-10-02
US20040024035A1 (en) 2004-02-05
WO2001077107A1 (fr) 2001-10-18
EP1268473A1 (fr) 2003-01-02
US6716863B2 (en) 2004-04-06
CN1444582A (zh) 2003-09-24
CZ20023264A3 (cs) 2003-02-12
MXPA02009621A (es) 2003-05-14
EE200200576A (et) 2004-06-15
BR0109851A (pt) 2003-06-03
HUP0300434A2 (hu) 2003-06-28
US20020173526A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
WO2001077107A8 (fr) Production et utilisation de composes heterocycliques
CO5280078A1 (es) Compuestos
YU17092A (sh) Derivati 2,4-diaminohinazolina
EP1288199A4 (fr) Inhibiteurs de mmp-12
EP0931788A3 (fr) Inhibiteurs de la métalloprotéinase
WO2002074726A3 (fr) Inhibiteurs de phosphodiesterase 4
CO5031285A1 (es) Triarilimidazoles
AU1180797A (en) Phenylimidazolidines and use thereof as an antiandrogenic agent
WO2001090071A3 (fr) Iminoazines substituees
MY104627A (en) A 1-pyridylimidazole derivative and its production and use.
EP1291344A4 (fr) Agents de controle de la piriculariose du riz
DK0862562T3 (da) Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
EP0908453A4 (fr)
EP0640586A4 (fr) Derive de stilbene et derive d'analogue de stilbene, et utilisation de ces derives.
WO2002024663A3 (fr) Composes pyrimidiques et leur utilisation
DK1086096T3 (da) Benzamider med tetrahydrofuranyloxy-substituenter som inhibitorer af phosphodiesterase 4
WO2002028844A1 (fr) Dérivés thiazole ou oxazole
WO2002000638A3 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
ES2078876A1 (es) Una composicion herbicida a base de fenilpirazol 3-sustituidos.
AU2001269540A1 (en) Serotonin reuptake inhibitors
CA2412596A1 (fr) Inhibiteurs de phosphodiesterase specifique de gmp cyclique
WO2003072576A3 (fr) Composes chimiques
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
CA2423357A1 (fr) Derives heterocycliques fusionnes utilises comme inhibiteurs de phosphodiesterase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09889974

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020017011568

Country of ref document: KR

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009621

Country of ref document: MX

Ref document number: PV2002-3264

Country of ref document: CZ

Ref document number: 2404760

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14132002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 152115

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/02290

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 018077927

Country of ref document: CN

Ref document number: IN/PCT/2002/1267/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200208126

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 522224

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001917827

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001244726

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4984

Country of ref document: GE

Ref document number: 1200201010

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2002 2002129898

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001917827

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3264

Country of ref document: CZ

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWR Wipo information: refused in national office

Ref document number: PV2002-3264

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001917827

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载